Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2024 | Overweight | Cantor Fitzgerald | |
7/23/2024 | $29.00 | Outperform | Leerink Partners |
7/23/2024 | $32.00 | Buy | Guggenheim |
7/23/2024 | $36.00 | Overweight | Morgan Stanley |
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
CORRECTION: Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating.
Guggenheim analyst Yatin Suneja initiates coverage on Alumis (NASDAQ:ALMS) with a Buy rating and announces Price Target of $32.
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Target of $13.
Leerink Partners analyst Thomas Smith initiates coverage on Alumis (NASDAQ:ALMS) with a Outperform rating and announces Price Target of $29.
Morgan Stanley analyst Terence Flynn initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Target of $36.
4/A - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
SC 13D - ALUMIS INC. (0001847367) (Subject)
SC 13G - ALUMIS INC. (0001847367) (Subject)
SC 13D - ALUMIS INC. (0001847367) (Subject)
SC 13D - ALUMIS INC. (0001847367) (Subject)
10-Q - ALUMIS INC. (0001847367) (Filer)
8-K - ALUMIS INC. (0001847367) (Filer)
D - ALUMIS INC. (0001847367) (Filer)
8-K - ALUMIS INC. (0001847367) (Filer)
8-K - ALUMIS INC. (0001847367) (Filer)
S-8 - ALUMIS INC. (0001847367) (Filer)
8-K - ALUMIS INC. (0001847367) (Filer)
4/A - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight
Leerink Partners initiated coverage of Alumis with a rating of Outperform and set a new price target of $29.00
Guggenheim initiated coverage of Alumis with a rating of Buy and set a new price target of $32.00
Morgan Stanley initiated coverage of Alumis with a rating of Overweight and set a new price target of $36.00
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceThursday, September 5, 2024, 8:30 am ETNew York, NY Format: fireside chat and one-on-one investor meetings 2024 Wells Fargo Healthcare ConferenceFriday, September 6, 2024Boston, MAFormat: one-on-one investor meetings only Baird 2
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program. This Phase 3 program consis